Drug Discovery & Development Insights by OmicsX
No Result
View All Result
  • Login
  • Register
  • Home
  • Channels
  • Startups
  • Pipeline
  • Drug Targets
  • Bio Partnering
  • Opinion
PRICING
SUBSCRIBE
  • Home
  • Channels
  • Startups
  • Pipeline
  • Drug Targets
  • Bio Partnering
  • Opinion
No Result
View All Result
Drug Discovery & Development Insights by OmicsX
No Result
View All Result
Home Oncology Small Molecules Kinase

Small Molecule Epigenetic Inhibitors – 2021

Insights on 20 Oncology Targeting Epigenetic Inhibitors in Active Development

Team OmicsX by Team OmicsX
May 30, 2022
in Uncategorized
497
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

EEpigenetics is a branch of genetics that studies the heritable changes of gene expression without changing the nucleotide sequence of genes. It is strictly regulated by a variety of chemical modifying enzymes and recognition proteins, which are often
called “writers”, “erasers”, and “readers”.411,412 The writers refer to
enzymes that transfer chemical groups to DNA or histones, which
include DNA methyltransferases (DNMTs), histone acetyltransferases
(HATs), and histone lysine methyltransferases (KMTs). The
erasers remove post-translational modifications, and include
histone deacetylases (HDACs) and histone lysine demethylases
(KDMs). The readers are proteins that can recognize the modified
histones or DNA, such as methyl-binding domain proteins, and
bromodomain and extra-terminal (BET) family proteins (Fig. 3).
Abnormal epigenetic regulation is also closely related to various
diseases including tumor, immune diseases, and many rare
diseases. Though numerous epigenetic regulatory proteins have
been identified as potential disease targets, only fewer epigenetic
drugs are approved for clinical use at present.
EZH2 Inhibitors
Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, functions as a catalytic subunit of the polycomb repressor complex 2 (PRC2), which also comprises other members including embryonic
ectoderm development (EED), suppressor of zeste 12 (SUZ12), and histone-binding proteins RbAp46/48.413 PRC2 is one of the two core complexes of polycomb group proteins (PcGs), and is responsible
for transferring methyl groups from S-adenosyl-L-methionine (SAM)
to lysine 27 on histone H3 (H3K27) through its C-terminal SET
domain, resulting in chromatin compaction and transcriptional
silencing of target genes. As the central component of PRC2, EZH2
is involved in numerous epigenetic modifications that are
associated with cell proliferation, differentiation, survival, adhesion,
and DNA damage repair. Dysfunction of EZH2 is closely related
to tumorigenesis and progression. Accumulating evidence has
confirmed that EZH2 is frequently mutated and abnormally
overexpressed in various malignant tumors including prostate
cancer,415,416 ovarian cancer,417 endometrial carcinoma,418 breast
cancer,419 melanoma as well as hematological malignancies,420
such as NHL, B-cell lymphoma, and T-cell ALL.421–424 It promotes
tumorigenesis mainly through three mechanisms: PRC2-dependent
H3K27 methylation, PRC2-dependent non-histone protein methylation,
and PRC2-independent coactivator of transcriptional factors.
Given the evidence for EZH2 enzymatic gain of function being a
cancer driver, inhibition of EZH2 has been thought of as a novel and
promising approach for cancer therapy

Global Oncology Intelligence Global Oncology Intelligence Global Oncology Intelligence
Previous Post

Kinase Inhibitors in Preclinical Development – 2021

Next Post

Small Molecule Epigenetic Drugs in Development – An Overview

Next Post

Small Molecule Epigenetic Drugs in Development – An Overview

Small Molecule Cancer Therapies

  • Kinase Inhibitors – An Overview
    • Receptor Tyrosine Kinase Inhibitors
    • Non Receptor Tyrosine Kinase Inhibitors
    • Serine/Theonine Kinase Inhibitors
    • Approved Kinase Inhibitors
    • Kinase Inhibitors in Clinical Development
    • Kinase Inhibitors in Preclinical Development
    • Kinase Inhibitors – Clinical Drug Developers
    • Kinase Inhibitors – Preclinical Drug Developers
  • Epigenetic Inhibitors – An Overview
    • Approved Epigenetic Inhibitors
Drug Discovery & Development Insights by OmicsX

Mapping Bio-Innovations

updated.. easy.. precise... complete...

Presenting filtered comprehensive information. Gain more insights on emerging bio-business, frame strategies, grow faster & better connect with biological science community.

LEARN MORE »

  • Trending
  • Comments
  • Latest
Approved Monoclonal Antibodies for Cancer Treatment

Approved Monoclonal Antibodies for Cancer Treatment

May 30, 2022
Approved Oncology Targeting Small Molecule Kinase Inhibitors

Approved Oncology Targeting Small Molecule Kinase Inhibitors

May 30, 2022

Kinase Inhibitors in Preclinical Development – 2021

May 30, 2022

Small Molecule Kinase Inhibitors – Preclinical Drug Developers

June 1, 2022

Small Molecule Kinase Inhibitors – Preclinical Drug Developers

0
Hoffmann-La Roche – Oncology Drug Pipeline Insights – June 2021

Hoffmann-La Roche –
Oncology Drug Pipeline Insights – June 2021

0
AbbVie, Inc. – Oncology Drug Pipeline Insights – June 2021

AbbVie, Inc. –
Oncology Drug Pipeline Insights – June 2021

0
Amgen, Inc.  Oncology Drug Pipeline Analysis – June 2021

Amgen, Inc.
Oncology Drug Pipeline Analysis – June 2021

0
Emerging Drug Developers Developing Cancer Targeting Exosomes

Emerging Drug Developers Developing Cancer Targeting Exosomes

July 10, 2022
Cancer Microbiome Targeting Emerging Drug Developers

Cancer Microbiome Targeting Emerging Drug Developers

July 9, 2022
Antibody Drug Conjugates

Antibody Drug Conjugates

June 18, 2022
Oncolytic Viruses

Oncolytic Viruses

June 29, 2022

Developed by OmicsX. The entirety of this site is protected by copyright © 2010–2021 HH BioTechnologies Private Ltd.

No Result
View All Result
  • Home
  • Subscription
  • Category
    • Opinion
    • Tech
  • Landing Page
  • Buy JNews
  • Support Forum
  • Pre-sale Question
  • Contact Us

Developed by OmicsX. The entirety of this site is protected by copyright © 2010–2021 HH BioTechnologies Private Ltd.

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

*By registering into our website, you agree to the Terms & Conditions and Privacy Policy.
All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?